PDS Biotech Pivots to PDS0301 After Strong mCRC Data
Event summary
- PDS0301 showed a 77.8% objective response rate in mCRC trial vs. 35% without it.
- 24-month survival rate with PDS0301 was ~80%, compared to ~35% without.
- Company will discontinue VERSATILE-003 Phase 3 trial for PDS0101 and seek partnerships.
- Q2 2026 net loss of $9.8M, down slightly from $9.4M in Q2 2025.
The big picture
PDS Biotech's strategic shift to prioritize PDS0301 follows compelling clinical data in metastatic colorectal cancer, positioning it as a potential leader in targeted IL-12 immunotherapies. The move reflects broader industry trends toward precision oncology and capital-efficient development strategies for biotechs with limited runway.
What we're watching
- Clinical Validation
- Whether PDS0301's strong mCRC results can translate to other solid tumors.
- Financial Discipline
- How long the remaining $5.6M cash balance will last amid refocused R&D spending.
- Partnership Strategy
- The pace at which PDS Biotech can secure external funding for PDS0101 development.
Related topics